|
1
|
Tran T, Davila JA and El-Serag HB: The
epidemiology of malignant gastrointestinal stromal tumors: An
analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol.
100:162–168. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miettinen M, Monihan JM, Sarlomo-Rikala M,
Kovatich AJ, Carr NJ, Emory TS and Sobin LH: Gastrointestinal
stromal tumors/smooth muscle tumors (GISTs) primary in the omentum
and mesentery: Clinicopathologic and immunohistochemical study of
26 cases. Am J Surg Pathol. 23:1109–1118. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: Review on morphology, molecular pathology,
prognosis, and differential diagnosis. Arch Pathol Lab Med.
130:1466–1478. 2006.PubMed/NCBI
|
|
4
|
Reith JD, Goldblum JR, Lyles RH and Weiss
SW: Extragastrointestinal (soft tissue) stromal tumors: An analysis
of 48 cases with emphasis on histologic predictors of outcome. Mod
Pathol. 13:577–585. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heinrich MC, Corless CL, Duensing A,
McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A,
Town A, et al: PDGFRA activating mutations in gastrointestinal
stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blanke CD, Demetri GD, von Mehren M,
Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD,
Roberts PJ, Heinz D, et al: Long-term results from a randomized
phase II trial of standard-versus higher-dose imatinib mesylate for
patients with unresectable or metastatic gastrointestinal stromal
tumors expressing KIT. J Clin Oncol. 26:620–625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yeh CN, Chen YY, Tseng JH, Chen JS, Chen
TW, Tsai CY, Cheng CT, Jan YY and Chen MF: Imatinib mesylate for
patients with recurrent or metastatic gastrointestinal stromal
tumors expressing KIT: A decade experience from Taiwan. Transl
Oncol. 4:328–335. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Demetri GD, van Oosterom AT, Garrett CR,
Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich
MC, Morgan JA, et al: Efficacy and safety of sunitinib in patients
with advanced gastrointestinal stromal tumour after failure of
imatinib: A randomised controlled trial. Lancet. 368:1329–1338.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Demetri GD, Reichardt P, Kang YK, Blay JY,
Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M,
Joensuu H, et al: Efficacy and safety of regorafenib for advanced
gastrointestinal stromal tumours after failure of imatinib and
sunitinib (GRID): An international, multicentre, randomised,
placebo-controlled, phase 3 trial. Lancet. 381:295–302. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lagarde P, Pérot G, Kauffmann A, Brulard
C, Dapremont V, Hostein I, Neuville A, Wozniak A, Sciot R,
Schöffski P, et al: Mitotic checkpoints and chromosome instability
are strong predictors of clinical outcome in gastrointestinal
stromal tumors. Clin Cancer Res. 18:826–838. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chibon F, Lagarde P, Salas S, Pérot G,
Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B,
et al: Validated prediction of clinical outcome in sarcomas and
multiple types of cancer on the basis of a gene expression
signature related to genome complexity. Nat Med. 16:781–787. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamaguchi U, Nakayama R, Honda K, Ichikawa
H, Hasegawa T, Shitashige M, Ono M, Shoji A, Sakuma T, Kuwabara H,
et al: Distinct gene expression-defined classes of gastrointestinal
stromal tumor. J Clin Oncol. 26:4100–4108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yen CC, Yeh CN, Cheng CT, Jung SM, Huang
SC, Chang TW, Jan YY, Tzeng CH, Chao TC, Chen YY, et al:
Integrating bioinformatics and clinicopathological research of
gastrointestinal stromal tumors: Identification of aurora kinase A
as a poor risk marker. Ann Surg Oncol. 19:3491–3499. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yeh CN, Yen CC, Chen YY, Cheng CT, Huang
SC, Chang TW, Yao FY, Lin YC, Wen YS, Chiang KC, et al:
Identification of aurora kinase A as an unfavorable prognostic
factor and potential treatment target for metastatic
gastrointestinal stromal tumors. Oncotarget. 5:4071–4086. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schaefer CF, Anthony K, Krupa S, Buchoff
J, Day M, Hannay T and Buetow KH: PID: The pathway interaction
database. Nucleic Acids Res. 37:D674–D679. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hirsch FR, Varella-Garcia M, Bunn PA Jr,
Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C and Franklin WA:
Epidermal growth factor receptor in non-small-cell lung carcinomas:
Correlation between gene copy number and protein expression and
impact on prognosis. J Clin Oncol. 21:3798–3807. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shan W, Akinfenwa PY, Savannah KB,
Kolomeyevskaya N, Laucirica R, Thomas DG, Odunsi K, Creighton CJ,
Lev DC and Anderson ML: A small-molecule inhibitor targeting the
mitotic spindle checkpoint impairs the growth of uterine
leiomyosarcoma. Clin Cancer Res. 18:3352–3365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lens SM, Voest EE and Medema RH: Shared
and separate functions of polo-like kinases and aurora kinases in
cancer. Nat Rev Cancer. 10:825–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia L, Li B and Yu H: The Bub1-Plk1 kinase
complex promotes spindle checkpoint signalling through Cdc20
phosphorylation. Nat Commun. 7:108182016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schaefer IM, Wang Y, Liang CW, Bahri N,
Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M,
Debiec-Rychter M, et al: MAX inactivation is an early event in GIST
development that regulates p16 and cell proliferation. Nat Commun.
8:146742017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schaefer IM, Mariño-Enríquez A and
Fletcher JA: What is new in gastrointestinal stromal tumor? Adv
Anat Pathol. 24:259–267. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Romero OA, Torres-Diz M, Pros E, Savola S,
Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, et
al: MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF
programs and is synthetic lethal with BRG1. Cancer Discov.
4:292–303. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Comino-Méndez I, Gracia-Aznárez FJ,
Schiavi F, Landa I, Leandro-Garcia LJ, Letón R, Honrado E,
Ramos-Medina R, Caronia D, Pita G, et al: Exome sequencing
identifies MAX mutations as a cause of hereditary pheochromocytoma.
Nat Genet. 43:663–667. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maltais L, Montagne M, Bédard M, Tremblay
C, Soucek L and Lavigne P: Biophysical characterization of the
b-HLH-LZ of ΔMax, an alternatively spliced isoform of Max found in
tumor cells: Towards the validation of a tumor suppressor role for
the Max homodimers. PLoS One. 12:e01744132017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Comino-Méndez I, Leandro-García LJ,
Montoya G, Inglada-Pérez L, de Cubas AA, Currás-Freixes M, Tysoe C,
Izatt L, Letón R, Gómez-Graña Á, et al: Functional and in silico
assessment of MAX variants of unknown significance. J Mol Med
(Berl). 93:1247–1255. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tabor V, Bocci M, Alikhani N, Kuiper R and
Larsson LG: MYC synergizes with activated BRAFV600E in mouse lung
tumor development by suppressing senescence. Cancer Res.
74:4222–4229. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Malumbres M: Physiological relevance of
cell cycle kinases. Physiol Rev. 91:973–1007. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Romeo S, Debiec-Rychter M, Van Glabbeke M,
Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier
P, Schneider U, et al: Cell cycle/apoptosis molecule expression
correlates with imatinib response in patients with advanced
gastrointestinal stromal tumors. Clin Cancer Res. 15:4191–4198.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
King SI, Purdie CA, Bray SE, Quinlan PR,
Jordan LB, Thompson AM and Meek DW: Immunohistochemical detection
of Polo-like kinase-1 (PLK1) in primary breast cancer is associated
with TP53 mutation and poor clinical outcom. Breast Cancer Res.
14:R402012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Z, Sun Y, Chen X, Squires J,
Nowroozizadeh B, Liang C and Huang J: p53 mutation directs AURKA
overexpression via miR-25 and FBXW7 in prostatic small cell
neuroendocrine carcinoma. Mol Cancer Res. 13:584–591. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hsu PK, Chen HY, Yeh YC, Yen CC, Wu YC,
Hsu CP, Hsu WH and Chou TY: TPX2 expression is associated with cell
proliferation and patient outcome in esophageal squamous cell
carcinoma. J Gastroenterol. 49:1231–1240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Glaser ZA, Love HD, Guo S, Gellert L,
Chang SS, Herrell SD, Barocas DA, Penson DF, Cookson MS and Clark
PE: TPX2 as a prognostic indicator and potential therapeutic target
in clear cell renal cell carcinoma. Urol Oncol. 35:286–293. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tomii C, Inokuchi M, Takagi Y, Ishikawa T,
Otsuki S, Uetake H, Kojima K and Kawano T: TPX2 expression is
associated with poor survival in gastric cancer. World J Surg
Oncol. 15:142017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang Z, Katsaros D, Shen Y, Fu Y, Canuto
EM, Benedetto C, Lu L, Chu WM, Risch HA and Yu H: Biological and
clinical significance of MAD2L1 and BUB1, genes frequently
appearing in expression signatures for breast cancer prognosis.
PLoS One. 10:e01362462015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun Q, Zhao H, Zhang C, Hu T, Wu J, Lin X,
Luo D, Wang C, Meng L, Xi L, et al: Gene co-expression network
reveals shared modules predictive of stage and grade in serous
ovarian cancers. Oncotarget. 8:42983–42996. 2017.PubMed/NCBI
|
|
37
|
Li L, Xu DB, Zhao XL and Hao TY:
Combination analysis of Bub1 and Mad2 expression in endometrial
cancer: Act as a prognostic factor in endometrial cancer. Arch
Gynecol Obstet. 288:155–165. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Z, Trope CG, Florenes VA, Suo Z,
Nesland JM and Holm R: Overexpression of CDC25B, CDC25C and
phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are
associated with malignant features and aggressive cancer
phenotypes. BMC Cancer. 10:2332010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nakamura N, Yamamoto H, Yao T, Oda Y,
Nishiyama K, Imamura M, Yamada T, Nawata H and Tsuneyoshi M:
Prognostic significance of expressions of cell-cycle regulatory
proteins in gastrointestinal stromal tumor and the relevance of the
risk grade. Hum Pathol. 36:828–837. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alin A: Multicollinearity. Wiley
Interdiscip Rev Comput Stat. 2:370–374. 2010. View Article : Google Scholar
|
